China Immunotech raises over ¥200M Series C for STAR-T cell therapy push
What's the deal? China Immunotech, a Beijing-based biotech firm, has closed a Series C round of more than 200,000,000 CNY (roughly $29.5 million). Zhengxingu CapitalDealroom has a profile for this one. Try Dealroom → led the round, with Fudan KechuangDealroom has a profile for this one. Try Dealroom → participating.
What's the endgame? The company plans to use the funds to advance registrational clinical development of YTS109, its universal STAR-T core product. It will also accelerate work on its in vivo STAR-T technology platform.
Why now? Beyond the clinical pipeline, the capital will fund a commercialisation system and a global intellectual property strategy — steps that point to a shift from research toward market readiness.
The signal: Cell therapy remains a magnet for Chinese venture capital, and China Immunotech's raise underscores continued investor appetite for universal, off-the-shelf approaches that aim to make treatments more scalable.
Read more: Jiemian News
Image credit: Generated with Gemini
